Skip to main content

Table 2 Concentrations of HBP, absolute neutrophil count and WBC in patients receiving daily filgrastim 300 microgr/day or placebo

From: Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim) – a prospective, placebo-controlled, double-blind study

 

Baseline

Day 4‡

Day 7

Filgrastim

Placebo

Filgrastim

Placebo

Filgrastim

Placebo

HBP (ng/ml)

23.6 (13.9-43.0)

21.6 (16.9-28.7)

25.1 (17.7-35.5)*

13.9 (12.0-19.5)

15.9 (12.6-20.7)

17.8 (13.6-20.9)

Neutrophil count (x109)/L

7.3 (4.0-11.1)

8.2 (3.6-12.8)

24.0 (14.6-32.8)†

9.4 (7.5-13.7)

27.1 (18.7-38.9)†

9.4 (6.1-12.0)

WBC count (x109)/L

9.1 (5.6-12.3)

12.1 (4.3-17.1)

27.2 (17.6-36.0)†

12.1 (10.0-16.5)

29.7 (20.1-39.8)†

12.2 (14.9)

HBP/WBC –ratio

2.9 (1.4-8.7)

2.8 (1.5-11.0)

0.9 (0.6-1.7)*

0.7 (0.5-0.9)

1.6 (1.1-2.1) †

0.7 (0.7-1.0)

HBP/Neutrophil –ratio

4.0 (1.7-9.8)

3.0 (1.6-12.5)

1.2 (0.7-2.2)

1.8 (1.3-2.4)

0.7 (0.5-1.2)*

1.7 (1.3-2.1)

  1. Median (IQR), WBC white blood cell count.
  2. * p < 0.05 filgrastim vs. placebo.
  3. † p < 0.001 filgrastim vs. placebo.
  4. ‡ Neutrophil count and WBC count from day 3.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us